Trends and challenges in the Pharma and Life Science Industry

Since 2020, there have been numerous quantum-related activities and experiments in the field of life sciences, spanning genomics, clinical research and discovery, diagnostics, treatments and interventions. AI-driven drug discovery continues to gain momentum and achieve critical milestones. Quantum-based algorithms can outperform existing computer algorithms, enabling better analysis of integrated patient data at scale.

As an example, IBM’s Policy Lab takes a proactive approach to providing policymakers with a vision and actionable recommendations to harness the benefits of innovation while ensuring trust in a world being reshaped by data. While AI technology has been around for decades, its adoption in life sciences has accelerated over the last several years, impacting drug development, clinical trials and supply chains. To keep selling meds and getting paid for them, patients need to be taking them continuously. Adherence and persistence are major challenges in an industry that caters to chronic patients. An analytics and AI-driven approach to engagement with clinicians provides the highest impact as it improves both their speed-to-decision and their awareness of the latest clinical evidence.

Strong demand can help companies overcome business challenges and position the industry for steady innovation-led growth. They must focus on business model specialization across innovation and invention, generics business and consumer health. Life sciences companies, particularly in pharma and biotech, can prove resilient despite inflationary pressures. They will seek opportunity to influence AI-health policy and deliver ethical and responsible AI-powered solutions that augment their existing product portfolio and improve patient and provider experiences and healthcare outcomes at reduced costs. Life sciences organizations will differentiate themselves by having a seat at the table. IBM works with organizations and policymakers to share our perspective to support responsible innovations.

While these changes present significant opportunities, they also bring new challenges that require companies to adapt quickly. By leveraging advanced technologies, fostering collaborations, and implementing effective quality management systems, companies can enhance supply chain resilience, maintain regulatory compliance, and ultimately deliver safe and effective products to patients in need. Supply chain management in the life science industry is a complex endeavor that requires meticulous attention to quality and regulatory requirements. Companies must adhere to various regulations, such as Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), and Good Clinical Practices (GCP), depending on the specific area of operation. Quality and regulatory compliance are paramount in the life science industry, given the critical nature of the products and the potential impact on patient health.

Aon is in the business of better decisions.

Recruiting in highly regulated environments, such as clinical trials, compliance, and R&D, presents its own set of challenges. In the life sciences sector, regulatory compliance isn't just a checkbox—it's a cornerstone of the entire operation. These stats highlight the transformative impact of AI in the life sciences industry, particularly in accelerating drug discovery and development. Finding talent that can keep up with this pace of innovation is a constant challenge, one that requires a deep understanding of both the technology and the market forces at play.

Digital Transformation and Cybersecurity in Health Research: Protecting Data in a Connected World

This includes delivering whole-genome sequencing at accessible and practical price points for researchers, scientists, doctors and patients. These questions and many more spanning payment models, consumer experience, supply chain and manufacturing will need to be addressed. How will they efficiently determine which patients are eligible for these therapies? We view ourselves as a supply chain organization, and a significant part of the value we bring to patients lies in optimizing our global supply chain and inventory. David Volk, executive director of clinical supply chain planning at Roche states, “We are a networked organization… collaborating much more broadly across all our partners and the industry. In the wake of COVID-19, we observe leaders viewing the supply chain as a core organizational function rather than a supportive one.

Looking Ahead: Building a Sustainable Talent Ecosystem

We’re not just looking for experts in current technologies; we need forward-thinking individuals who can adapt and grow with the industry. Over the years, I’ve seen many promising candidates fall short because they lack this critical intersection of skills. Finding candidates who not only possess advanced scientific knowledge but also understand the regulatory and commercial landscapes is a tall order.

Hiring candidates with knowledge of FDA, EMA, and other global regulatory standards ensures compliance and helps bring products to market efficiently, avoiding costly delays or penalties. Companies need to adopt strategic approaches to attract challenges in life sciences industry and retain top talent in this competitive sector. Contact us today to discuss how our tailored recruitment solutions can help you overcome talent acquisition hurdles and build a high-performing team for the future." At Cerca Talent, we specialize in connecting innovative companies with the right professionals who drive growth and success. Strategic recruitment and retention are not just optional—they are essential for driving innovation and maintaining competitiveness in this fast-paced sector.

Astrix specializes in supporting organizations as they navigate these challenges. Investing in education, reskilling, and inclusive workplace practices will ensure a robust talent pipeline for years. These firms provide a crucial resource for companies that need more internal recruitment bandwidth or need to scale quickly. These factors collectively hinder the industry’s ability to deliver transformative health solutions efficiently.

Whether it’s biotechnology, pharmaceuticals, or medical devices, the industry demands a unique blend of technical expertise and industry-specific experience. In this article, I’ll delve into the unique challenges we face in recruiting top-tier talent within the life sciences sector, and why these challenges require a specialized, nuanced approach. Over the past 20 years, I’ve seen first-hand how this industry has evolved, not just in terms of technological breakthroughs but in the way talent acquisition is handled. The life sciences industry stands as one of the most dynamic and impactful sectors of our time. Contact Astrix today to learn how we can help your organization build a future-ready talent ecosystem. By partnering with us, your organization gains a trusted ally in overcoming workforce shortages, fostering innovation, and driving impactful advancements in global health.

• Along with these challenges, the ongoing drive to reduce costs, improve efficiency and productivity, drive better decision-making and reduce risk will continue to drive pharma investment in cloud, AI/ML, analytics and automation in 2023 despite higher interest rates.
• AI’s ability to process large volumes of data improves efficiency and accuracy, providing significant value in managing the complexities of the industry.
• This includes better training programs, developing clear career paths and opportunities for high-performing individuals and teams, and intentionally building an engaging, team-oriented work environment.
• The focus on person-centered care is stronger than ever with the rise of precision medicine and the unanswered questions of how to scale personalized therapies and experiences that bring new hope to millions.
• Managing multiple assets in parallel requires stronger planning, dependency tracking, and risk oversight.

Learn more in Slalom’s AI research report.

This turnover can severely impact innovation and productivity, disrupting ongoing projects and delaying critical research and development efforts. However, attracting and retaining diverse candidates in this industry remains a challenge, particularly given the historical lack of representation in certain roles. Successful cross-border recruitment demands a nuanced approach that balances global reach with local understanding. Hiring internationally for life sciences roles introduces a host of challenges, from navigating different labor laws to understanding cultural differences. Overcoming these regional shortages requires innovative strategies, such as remote work options, relocation packages, or partnerships with local academic institutions to develop talent pipelines. Geographic location plays a significant role in talent availability within the life sciences industry.

However, the widening skills gap poses a threat to its progress. The life sciences industry drives global health innovation, enabling breakthroughs in drug discovery, genomics, biotechnology, and more. Acting boldly in 2023 with a clearly articulated strategy and prioritization will set both mature life sciences organizations and new players on the right path.

Quantum computing will enable more advanced DCT capabilities for recruitment, trial site selection, and optimization and patient surveillance. There is a clear need to improve study formats so broader, more equitable populations are accessed and included. Limitations of traditional clinical trials were amplified during the COVID-19 pandemic and have accelerated the use of decentralized clinical trials (DCTs). An example is the new Illumina NovaSeq X sequencer released in September 2022, which is twice as fast as prior models and capable of sequencing 20,000 genomes per year at a cost of $200 per genome.

How small defects turn into late decisions, unstable commitments, and customer impact Why restoring decision flow is what brings control back to operations Companies that proactively adapt to these trends will be best positioned for success. The transition from Computer System Validation (CSV) to Computer Software Assurance (CSA) represents a significant change in how systems are tested and validated. The cloud brings a lot of value in many senses, but it also enforces some changes.

Business leaders will focus on supply chain solutions that drive transparency across sourcing, manufacturing, delivery and logistics while minimizing cost, waste and time. The upheaval and disruption caused by COVID-19 has given pharma leaders a heightened awareness of resiliency in delivering innovative drugs and therapeutics to communities, underscoring the importance of investing in forecasting and supply chains. We predict companies will make significant strides towards digitization to reduce cost, improve quality, reduce recalls and improve safety. The costs of operating manufacturing facilities will increase as energy prices continue to rise. Recruiting on-site patients and maintaining on-site trials remains prohibitively expensive. We don’t just deliver technology, we work shoulder to shoulder with our clients to ensure technology drives impact when and where it matters most.